Tegafur-uracil

(Redirected from Tegafur)
Jump to: navigation, search

WikiDoc Resources for Tegafur-uracil

Articles

Most recent articles on Tegafur-uracil

Most cited articles on Tegafur-uracil

Review articles on Tegafur-uracil

Articles on Tegafur-uracil in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Tegafur-uracil

Images of Tegafur-uracil

Photos of Tegafur-uracil

Podcasts & MP3s on Tegafur-uracil

Videos on Tegafur-uracil

Evidence Based Medicine

Cochrane Collaboration on Tegafur-uracil

Bandolier on Tegafur-uracil

TRIP on Tegafur-uracil

Clinical Trials

Ongoing Trials on Tegafur-uracil at Clinical Trials.gov

Trial results on Tegafur-uracil

Clinical Trials on Tegafur-uracil at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Tegafur-uracil

NICE Guidance on Tegafur-uracil

NHS PRODIGY Guidance

FDA on Tegafur-uracil

CDC on Tegafur-uracil

Books

Books on Tegafur-uracil

News

Tegafur-uracil in the news

Be alerted to news on Tegafur-uracil

News trends on Tegafur-uracil

Commentary

Blogs on Tegafur-uracil

Definitions

Definitions of Tegafur-uracil

Patient Resources / Community

Patient resources on Tegafur-uracil

Discussion groups on Tegafur-uracil

Patient Handouts on Tegafur-uracil

Directions to Hospitals Treating Tegafur-uracil

Risk calculators and risk factors for Tegafur-uracil

Healthcare Provider Resources

Symptoms of Tegafur-uracil

Causes & Risk Factors for Tegafur-uracil

Diagnostic studies for Tegafur-uracil

Treatment of Tegafur-uracil

Continuing Medical Education (CME)

CME Programs on Tegafur-uracil

International

Tegafur-uracil en Espanol

Tegafur-uracil en Francais

Business

Tegafur-uracil in the Marketplace

Patents on Tegafur-uracil

Experimental / Informatics

List of terms related to Tegafur-uracil


Overview

Tegafur-uracil is a chemotherapy drug used in the treatment of cancer, primarily bowel cancer. It is also called UFT or UFUR.[1]

UFT is the first generation of DIF(DPD Inhibitory Flouropyrimidine)drug. UFT is an oral agent with combines uracil, a competitive inhibitor of DPD, with the 5-FU prodrug tegafur in a 4:1 molar ratio. Excess uracil competes with 5-FU for DPD, thus inhibiting 5-FU catabolism.

References



Linked-in.jpg